---
title: "Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Indication questions"
description: "Indication questions on Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is Imbruvica approved for in CLL and SLL? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Indication questions

Manufacturer: Pharmacyclics LLC; Janssen Biotech, Inc.  
Prescribing information: [Imbruvica](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf)

Indication questions that apply to every indication of Imbruvica are on [Imbruvica (ibrutinib), all indications: Indication](https://www.evicenter.com/medical-information/imbruvica/indication).

## Indication

<a id="imbruvica-cll-indication"></a>

### What is Imbruvica approved for in CLL and SLL?

> “1.1 
> Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 
> IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia 
> (CLL)/small lymphocytic lymphoma (SLL). 
> 1.2 
> Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion 
> IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia 
> (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion.”

Source: [IMBRUVICA: Prescribing information, page 2, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=2)

## Related pages
- [Medical information: Imbruvica (ibrutinib): Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma)
- [Clinical trials](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/guidelines)
